L
Lawrence Deyton
Researcher at National Institutes of Health
Publications - 39
Citations - 6124
Lawrence Deyton is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Zidovudine. The author has an hindex of 23, co-authored 37 publications receiving 6049 citations. Previous affiliations of Lawrence Deyton include George Washington University & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Scott M. Hammer,Kathleen Squires,Michael Hughes,Michael Hughes,Janet M. Grimes,Lisa M. Demeter,Judith S. Currier,Joseph J. Eron,Judith Feinberg,Henry H. Balfour,Lawrence Deyton,Chodakewitz Jeffrey A,Margaret A. Fischl,John P. Phair,William Spreen,Louise Pedneault,Bach-Yen Nguyen,Jon C. Cook +17 more
TL;DR: In this article, the efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear.
Journal ArticleDOI
Guidelines for preventing opportunistic infections among HIV-infected persons - 2002
Henry Masur,Jonathan E. Kaplan,King K. Holmes,Beverly Alston,Miriam J. Alter,Neil M. Ampel,Jean Anderson,A. Cornelius Baker,David A Barr,John G. Bartlett,John E. Bennett,Constance A. Benson,William A. Bower,Samuel A. Bozzette,John T. Brooks,Victoria A. Cargill,Kenneth G. Castro,Richard E. Chaisson,David A. Cooper,Clyde S. Crumpacker,Judith S. Currier,Kevin M. DeCock,Lawrence Deyton,Scott F. Dowell,W. Lawrence Drew,William Duncan,Mark S. Dworkin,Clare A. Dykewicz,Robert W Eisinger,Tedd Ellerbrock,Wafaa El-Sadr,Judith Feinberg,Kenneth A. Freedberg,Keiji Fukuda,Hansjakob Furrer,Jose M. Gatell,John W. Gnann,Mark J. Goldberger,Sue Goldie,Eric P. Goosby,Fred M. Gordin,Peter A. Gross,Rana Hajjeh,Richard Hafner,Diane Havlir,S D Holmberg,David R. Holtgrave,Thomas M. Hooton,Douglas A. Jabs,Mark A. Jacobson,Harold Jaffe,Edward N. Janoff,Jeffrey M. Jones,Dennis D. Juranek,Mari M. Kitahata,Joseph A. Kovacs,Catherine Leport,Myron J. Levin,Juan C. Lopez,Jens D Lundgren,Michael Marco,Eric Mast,Douglas L. Mayers,Lynne M. Mofenson,Julio Montaner,Richard A. Moore,Thomas Navin,James D. Neaton,Charles Nelson,Joseph F. O'Neill,Joel Palefsky,Alice Pau,Phil Pellett,John P. Phair,Steve Piscitelli,Michael A. Polis,Thomas C. Quinn,William C. Reeves,Peter Reiss,David Rimland,Anne Schuchat,Cynthia L. Sears,Leonard B. Seeff,Kent A. Sepkowitz,Kenneth E. Sherman,Thomas G. Slama,Elaine M. Sloand,Stephen A. Spector,John A. Stewart,David L. Thomas,Timothy M. Uyeki,Russell Van Dyke,M. Elsa Villarino,Anna Wald,D. Heather Watts,L. Joseph Wheat,Paige L. Williams,Thomas C. Wright +97 more
TL;DR: This fourth edition of the guidelines for preventing opportunistic infections (OIs) among persons infected with human immunodeficiency virus (HIV) is intended for clinicians and other health-care providers who care for HIV-infected persons.
Journal ArticleDOI
CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection.
Henry Masur,Frederick P. Ognibene,Robert Yarchoan,James H. Shelhamer,Barbara F. Baird,William D. Travis,Anthony F. Suffredini,Lawrence Deyton,J A Kovacs,Judith Falloon +9 more
TL;DR: Pneumocystis pneumonia, cytomegalovirus pneumonia, and pulmonary infection caused by C. neoformans or M. avium-intracellulare are unlikely to occur in HIV-infected patients who have had a CD4 count above 0.200 to 0.250 X 10(9) cells/L or aCD4 percent above 20% to 25% in the 60 days before pulmonary evaluation.
Journal ArticleDOI
Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial
Richard T. D'Aquila,Michael Hughes,Victoria A. Johnson,Margaret A. Fischl,Jean Pierre Sommadossi,Song Heng Liou,Joseph Timpone,Maureen Myers,Nesli Basgoz,Manette T. Niu,Martin S. Hirsch,Michael S. Saag,Jill Weingarten,John W. Gnann,Diane V. Havlir,Chris Fegan,Stephen A. Spector,Douglas D. Richman,Mark A. Jacobson,Kathy Dybeck,Patrick Joseph,Kathleen Clanon,Stacey McKenzie,Pam Daniel,Dale Dayton,Jill Leonard,Robert Schooley,Daniel Kuritzkes,Graham Ray,Beverly Putnam,Dushyantha Jayaweera,Janie Patrone-Reese,Thomas Tanner,Jo Moebus,Nancy Reed,Renee St Jacque,Keith Henry,Susan Swindells,Joe Eron,David Ragan,James Horton,Timothy G. Lane,Ian Frank,Anne Norris,Roger Pomerantz,Stephen Hauptman,Jan Geiseler,John M. Leedom,Frances Canchola,Connie Olson,Lawrence Deyton,Carla Pettinelli +51 more
TL;DR: This multicenter, randomized trial was AIDS (acquired immunodeficiency syndrome) and tested whether this triple combination would improve immunologic and virologic effects in vivo by comparing it with a combination of zidovudine and didanosine in a 48-week phase II, randomized clinical trial in adults with HIV-1 disease who had previously received prolonged nucleoside therapy.
Journal ArticleDOI
Anti-retroviral effects of interferon-α in AIDS associated Kaposi's sarcoma
H. Clifford Lane,Judith Feinberg,Victoria J. Davey,Lawrence Deyton,Michael Baseler,Jody Manischewitz,Henry Masur,J A Kovacs,Betsey Herpin,Robert L. Walker,JuliaA Metcalf,Norman Salzman,Gerald V. Quinnan,AnthonyS Fauci +13 more
TL;DR: The potential benefits, both anti-tumour and anti-retroviral, of treatment with IFN-α in the early stages of HIV infection and Kaposi's sarcoma are demonstrated.